North America Hyaluronidase Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$373.6

Forecast, 2030 (US$M)

$642.1

CAGR, 2024 - 2030

Report Coverage

North America

North America hyaluronidase market, 2018-2030 (US$M)

Related Markets

Global Hyaluronidase Industry Outlook

Europe Hyaluronidase Market Outlook

Asia Pacific Hyaluronidase Market Outlook

Latin America Hyaluronidase Market Outlook

MEA Hyaluronidase Market Outlook

North America hyaluronidase market highlights

The North America hyaluronidase market generated a revenue of USD 373.6 million in 2023.
The market is expected to grow at a CAGR of 8% from 2024 to 2030.
In terms of segment, animal-derived hyaluronidase was the largest revenue generating type in 2023.
Animal-derived Hyaluronidase is the most lucrative type segment registering the fastest growth during the forecast period.

North America data book summary

Market revenue in 2023	USD 373.6 million
Market revenue in 2030	USD 642.1 million
Growth rate	8% (CAGR from 2023 to 2030)
Largest segment	Animal-derived hyaluronidase
Fastest growing segment	Animal-derived Hyaluronidase
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Animal-derived Hyaluronidase
Key market players worldwide	Bausch & Lomb Corp, The Cooper Companies Inc, Sun Pharmaceutical Industries, STEMCELL Technologies, Amphastar Pharmaceuticals Inc, Prima Pharm, Halozyme Therapeutics, Shreya Life Sciences

Other key industry trends

In terms of revenue, North America region accounted for 37.9% of the global hyaluronidase market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 382.0 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Hyaluronidase Market Scope

Hyaluronidase market segmentation & scope

Type

Animal-derived Hyaluronidase

Synthetic Hyaluronidase

Application

Dermatology

Chemotherapy

Ophthalmology

Plastic Surgery

Others

Regions

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Countries

U.S.

Canada

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Japan

China

India

Australia

South Korea

Thailand

Mexico

Brazil

South Africa

Saudi Arabia

Argentina

UAE

Kuwait

Hyaluronidase Market Companies

Name	Profile	# Employees	HQ	Website

North America hyaluronidase market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hyaluronidase market will help companies and investors design strategic landscapes.

Animal-derived hyaluronidase was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America hyaluronidase market based on animal-derived hyaluronidase covering the revenue growth of each sub-segment from 2018 to 2030.

The first hyaluronic acid injectable filler was approved by the U.S. FDA in 2003, and since then the use of HA fillers for several cosmetic procedures has elevated in the region. The very first fillers approved by the FDA were manufactured by Merz North America, Inc. under the brand names Radiesse and Belotero Balance.

With increasing use of such popular HA injectable fillers across North America, the pool of entities investing in the development of hyaluronidase products aimed at treating misplaced fillers and associated side effects.

Several key players are operating in North America hyaluronidase market. These include Amphastar Pharmaceuticals, Inc., Halozyme Therapeutics, PrimaPharm, Inc., Bausch & Lomb Incorporated, CooperSurgical Fertility Company.

Reasons to subscribe to North America hyaluronidase market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America hyaluronidase market databook

Our clientele includes a mix of hyaluronidase market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America hyaluronidase market , including forecasts for subscribers. This continent databook contains high-level insights into North America hyaluronidase market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list